製药业的人工智慧：全球市场

预计全球製药业人工智慧市场规模将从 2025 年的 38 亿美元成长到 2030 年底的 152 亿美元，2025 年至 2030 年的复合年增长率为 31.7%。

预计北美市场将从2025年的23亿美元成长到2030年底的96亿美元，复合年增长率为32.9%。预计亚太市场将从2025年的4.963亿美元成长到2030年底的23亿美元，复合年增长率为36.0%。

本报告调查了製药业人工智慧的全球市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测以及各个细分市场和地区的详细分析。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场摘要
• 市场动态与成长要素
• 新兴技术
• 細項分析
• 区域分析
• 结论

第二章 市场概况

• 当前市场概况
• 宏观经济因素分析
• 政府政策法规
• 技术基础设施和数位化准备
• 全球贸易与供应链动态
• 美国关税的影响
• 波特五力分析
• 人工智慧对医药价值链的影响
• 药物发现与临床前开发：加速创新
• 临床试验：更聪明的设计与执行
• 製造和供应链：智慧运营
• 监管事务与合规：自动化与准确性
• 商业化与市场进入：数据主导策略
• 上市后监督：持续学习与安全监测
• 用例
• 使用案例1：产生式人工智慧简化监理备案流程
• 使用案例2：基于 AI 的合成路线研发助手

第三章 市场动态

• 市场动态
• 市场驱动因素
• 加速药物发现和开发
• 人工智慧在临床试验中的应用日益广泛
• 精准医疗与人工智慧应用的需求
• 市场限制
• 监管和道德问题
• 数据挑战
• 市场机会
• 合作与投资
• 新兴国家对药物研发的关注度日益提高
• 分子设计中生成式人工智慧的进展

第四章：监理现状

• 概述
• 美国监管情景
• 欧洲监管情景
• 日本的监管状况
• 中国的监管情势
• 其他的

第五章新兴趋势与通路分析

• 新趋势
• 製药业的生成式人工智慧
• 联邦学习
• 自然语言处理
• 生成对抗网络
• 管道分析
• 摘要
• 专利分析
• 调查结果

第六章 市场区隔分析

• 细分市场
• 按产品类型分類的市场
• 摘要
• 软体
• 服务
• 市场区隔：按应用
• 摘要
• 药物研发
• 临床试验
• 个人化医疗
• 其他的
• 地理分布
• 市场区隔：按地区
• 摘要
• 北美洲
• 欧洲
• 亚太地区
• 世界其他地区

第七章 竞争讯息

• 摘要
• 竞争分析
• 战略分析
• 投资状况

第八章 人工智慧在製药市场的永续性：ESG 视角

• ESG：简介
• 永续性趋势和倡议
• ESG风险评估
• BCC的结语

第九章 附录

• 调查方法
• 来源
• 简称
• 公司简介
• AICURE
• ATOMWISE INC.
• BENEVOLENTAI
• GOOGLE DEEPMIND
• HEALX
• IKTOS
• INSILICO MEDICINE
• INVENIAI LLC.
• NVIDIA CORP.
• PATHAI INC.
• RECURSION
• SCHRODINGER INC.
• SYRENCLOUD INC.
• TEMPUS AI INC.
• XTALPI INC.
• 新兴Start-Ups/市场颠覆者

The global market for artificial intelligence (AI) in pharmaceuticals is estimated to grow from $3.8 billion in 2025 to reach $15.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 31.7% from 2025 through 2030.

The North American market for AI in pharmaceuticals is estimated to grow from $2.3 billion in 2025 to reach $9.6 billion by the end of 2030, at a CAGR of 32.9% from 2025 through 2030.

The Asia-Pacific market for AI in pharmaceuticals is estimated to grow from $496.3 million in 2025 to reach $2.3 billion by the end of 2030, at a CAGR of 36.0% from 2025 through 2030.

Report Scope

This report on the global market for AI in pharmaceuticals explores market dynamics and trends, and analyzes technological developments, software performance, clinical trials, new product approvals and emerging technologies. The report also includes profiles of leading companies and their strategies.

The report explores how AI is transforming the pharmaceutical industry through enhanced diagnostic capabilities, early disease detection, clinical trial optimization, drug discovery and personalized treatment planning. It also examines AI disruption across industry verticals and value chain stages, while presenting market spending patterns, investment forecasts, R&D expenditures and venture capital funding. The report segments the market by product type, application and region. Types include software and services. Applications include drug discovery and development, clinical trials, personalized medicines and others. The four regions covered are North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data has been provided for 2024 as the base year, with forecasts for 2025 through 2030.

Report Includes

• 27 data tables and 62 additional tables
• An analysis of the global markets for artificial intelligence (AI) in the pharmaceuticals industry
• Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the market's size and revenue growth prospects, accompanied by a market share analysis by product type, application and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as a global supply chain analysis
• Case studies on AI implementation to streamline processes across drug discovery and development, manufacturing, quality control and patient care
• A relevant patent analysis, featuring key granted and published patents
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Google DeepMind, Atomwise Inc., Insilico Medicine, Recursion Pharmaceuticals and Nvidia Corp.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Macroeconomic Factors Analysis
• Government Policy and Regulation
• Technological Infrastructure and Digital Readiness
• Global Trade and Supply Chain Dynamics
• Impact of U.S. Tariffs
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate to High)
• Bargaining Power of Suppliers (Low to Moderate)
• Bargaining Power of Buyers (High)
• Threat of Substitute Products or Services (Low to Moderate)
• Industry Level of Competitiveness (High)
• AI's Impact on the Pharmaceutical Value Chain
• Drug Discovery and Preclinical Development: Accelerated Innovation
• Clinical Trials: Smarter Design and Execution
• Manufacturing and Supply Chain: Intelligent Operations
• Regulatory Affairs and Compliance: Automation and Accuracy
• Commercialization and Market Access: Data-Driven Strategies
• Post-Market Surveillance: Continuous Learning and Safety Monitoring
• Use Cases
• Use Case 1: Generative AI for Efficiency in Regulatory Submissions
• Use Case 2: Generative AI-Enabled R&D Assistant for Synthesis Routes

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Faster Drug Discovery and Development
• Increasing Adoption of AI in Clinical Trials
• Demand for Precision Medicine and AI Applications
• Market Restraints
• Regulatory and Ethical Concerns
• Data Challenges
• Market Opportunities
• Collaborations and Investments
• Increased Focus on Drug Discovery in Emerging Nations
• Advances of Generative AI in Molecular Design

Chapter 4 Regulatory Landscape

• Overview
• Regulatory Scenario in the U.S.
• Regulatory Scenario in Europe
• Regulatory Scenario in Japan
• Regulatory Scenario in China
• Other Countries

Chapter 5 Emerging Trends and Pipeline Analysis

• Emerging Trends
• Generative AI in Pharma
• Federated Learning
• Natural Language Processing
• Generative Adversarial Networks
• Pipeline Analysis
• Takeaways
• Patent Analysis
• Findings

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Market Breakdown, by Product Type
• Takeaways
• Software
• Services
• Market Breakdown, by Application
• Takeaways
• Drug Discovery and Development
• Clinical Trials
• Personalized Medicine
• Other Applications
• Geographic Breakdown
• Market Breakdown, by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 7 Competitive Intelligence

• Takeaways
• Competitive Analysis
• Strategic Analysis
• Investment Landscape

Chapter 8 Sustainability in AI in the Pharmaceutical Industry: ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives
• ESG Risk Ratings
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• AICURE
• ATOMWISE INC.
• BENEVOLENTAI
• GOOGLE DEEPMIND
• HEALX
• IKTOS
• INSILICO MEDICINE
• INVENIAI LLC.
• NVIDIA CORP.
• PATHAI INC.
• RECURSION
• SCHRODINGER INC.
• SYRENCLOUD INC.
• TEMPUS AI INC.
• XTALPI INC.
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for AI in Pharmaceuticals, by Region, Through 2030
• Table 1 : Collaborations Between AI Software and Pharmaceutical Companies
• Table 2 : FDA AI/ML Initiatives and Milestones, 2014 and 2025
• Table 3 : EMA AI/ML Regulatory Development Timeline, 2021-2024
• Table 4 : Clinical Trial Data for AI in Pharmaceutical Drugs, 2025
• Table 5 : Granted Patents for AI in Pharmaceuticals, 2022-2025
• Table 6 : Global Market for AI in Pharmaceuticals, by Product Type, Through 2030
• Table 7 : Global Market for AI Software in Pharmaceuticals, by Region, Through 2030
• Table 8 : Global Market for Services in AI in Pharmaceuticals, by Region, Through 2030
• Table 9 : Global Market for AI in Pharmaceuticals, by Application, Through 2030
• Table 10 : AI Tools Used in Drug Discovery
• Table 11 : AI-Enabled Drugs Entering the Clinical Phase, 2025
• Table 12 : Global Market for AI in Drug Discovery and Development, by Region, Through 2030
• Table 13 : Partnerships Between Pharmaceutical and Technology Companies, 2023-2025
• Table 14 : Advantages and Disadvantages of Using AI in Clinical Trials
• Table 15 : Global Market for AI in Pharmaceuticals for Clinical Trial Applications, by Region, Through 2030
• Table 16 : Applications of ML in Pharmacogenomics
• Table 17 : Global Market for AI in Pharmaceuticals for Personalized Medicine, by Region, Through 2030
• Table 18 : Global Market for Other Applications of AI in Pharmaceuticals, by Region, Through 2030
• Table 19 : Global Market for AI in Pharmaceuticals, by Region, Through 2030
• Table 20 : North American Market for AI in Pharmaceuticals, by Product Type, Through 2030
• Table 21 : North American Market for AI in Pharmaceuticals, by Application, Through 2030
• Table 22 : North American Market for AI in Pharmaceuticals, by Country, Through 2030
• Table 23 : European Market for AI in Pharmaceuticals, by Product Type, Through 2030
• Table 24 : European Market for AI in Pharmaceuticals, by Application, Through 2030
• Table 25 : European Market for AI in Pharmaceuticals, by Country, Through 2030
• Table 26 : Asia-Pacific Market for AI in Pharmaceuticals, by Product Type, Through 2030
• Table 27 : Asia-Pacific Market for AI in Pharmaceuticals, by Application, Through 2030
• Table 28 : Asia-Pacific Market for AI in Pharmaceuticals, by Country, Through 2030
• Table 29 : RoW Market for AI in Pharmaceuticals, by Product Type, Through 2030
• Table 30 : RoW Market for AI in Pharmaceuticals, by Application, Through 2030
• Table 31 : RoW Market for AI in Pharmaceuticals, by Sub-Region, Through 2030
• Table 32 : Leading Companies in the Global Market for AI in Pharmaceuticals, 2024
• Table 33 : Agreements, Collaborations and Partnerships in the Market for AI in Pharmaceuticals, 2022-2025
• Table 34 : M&A in the AI in Pharmaceuticals Industry, 2024-2025
• Table 35 : Recent Investments in the AI in Pharmaceuticals Industry, 2024 and 2025
• Table 36 : ESG Risk Rankings for AI in Pharmaceuticals Companies, 2025*
• Table 37 : Information Sources Used in this Report
• Table 38 : Abbreviations Used in this Report
• Table 39 : AiCure: Company Snapshot
• Table 40 : AiCure: Product Portfolio
• Table 41 : AiCure: News/Key Developments, 2024
• Table 42 : Atomwise Inc.: Company Snapshot
• Table 43 : Atomwise Inc.: Product Portfolio
• Table 44 : Atomwise Inc.: News/Key Developments, 2022
• Table 45 : BenevolentAI: Company Snapshot
• Table 46 : BenevolentAI: Product Portfolio
• Table 47 : BenevolentAI: News/Key Developments, 2022-2025
• Table 48 : Google DeepMind: Company Snapshot
• Table 49 : Google DeepMind: Product Portfolio
• Table 50 : Google DeepMind: News/Key Developments, 2024 and 2025
• Table 51 : Healx: Company Snapshot
• Table 52 : Healx: Product Portfolio
• Table 53 : Healx: News/Key Developments, 2023 and 2024
• Table 54 : Iktos: Company Snapshot
• Table 55 : Iktos: Product Portfolio
• Table 56 : Iktos: News/Key Developments, 2023-2025
• Table 57 : Insilico Medicine: Company Snapshot
• Table 58 : Insilico Medicine: Product Portfolio
• Table 59 : Insilico Medicine: News/Key Developments, 2023-2025
• Table 60 : InveniAI LLC.: Company Snapshot
• Table 61 : InveniAI LLC.: Product Portfolio
• Table 62 : InveniAI LLC.: News/Key Developments, 2021-2024
• Table 63 : Nvidia Corp.: Company Snapshot
• Table 64 : Nvidia Corp.: Financial Performance, FY 2023 and 2024
• Table 65 : Nvidia Corp.: Product Portfolio
• Table 66 : Nvidia Corp.: News/Key Developments, 2023-2025
• Table 67 : PathAI Inc.: Company Snapshot
• Table 68 : PathAI Inc.: Product Portfolio
• Table 69 : PathAI Inc.: News/Key Developments, 2024 and 2025
• Table 70 : Recursion: Company Snapshot
• Table 71 : Recursion: Financial Performance, FY 2023 and 2024
• Table 72 : Recursion: Product Portfolio
• Table 73 : Recursion: News/Key Developments, 2024 and 2025
• Table 74 : Schrodinger Inc.: Company Snapshot
• Table 75 : Schrodinger Inc.: Financial Performance, FY 2023 and 2024
• Table 76 : Schrodinger Inc.: Product Portfolio
• Table 77 : Schrodinger Inc.: News/Key Developments, 2023 and 2024
• Table 78 : SyrenCloud Inc.: Company Snapshot
• Table 79 : SyrenCloud Inc.: Product Portfolio
• Table 80 : Tempus AI Inc.: Company Snapshot
• Table 81 : Tempus AI Inc.: Financial Performance, FY 2023 and 2024
• Table 82 : Tempus AI Inc.: Product Portfolio
• Table 83 : Tempus AI Inc.: News/Key Developments, 2023-2025
• Table 84 : XtalPi Inc.: Company Snapshot
• Table 85 : XtalPi Inc.: Financial Performance, FY 2023 and 2024
• Table 86 : XtalPi Inc.: Product Portfolio
• Table 87 : XtalPi Inc.: News/ Key Developments, 2024 and 2025
• Table 88 : Emerging Startups in the Market for AI in Pharmaceuticals

List of Figures

• Summary Figure : Global Market Shares of AI in Pharmaceuticals, by Region, 2024
• Figure 1 : Applications of AI in the Drug Development and Distribution Life Cycle
• Figure 2 : Porter's Five Forces Analysis: AI in Pharmaceuticals Market
• Figure 3 : Applications of AI in the Pharmaceutical Value Chain
• Figure 4 : Market Dynamics of AI in Pharmaceuticals
• Figure 5 : Emerging Technologies of AI in the Pharmaceutical Market
• Figure 6 : Granted Patents for AI in Pharmaceuticals, by Year, 2021-2025
• Figure 7 : Global Market Shares of AI in Pharmaceuticals, by Product Type, 2024
• Figure 8 : Global Market Shares of AI Software in Pharmaceuticals, by Region, 2024
• Figure 9 : Global Market Shares of Services for AI in Pharmaceuticals, by Region, 2024
• Figure 10 : Global Market Shares of AI in Pharmaceuticals, by Application, 2024
• Figure 11 : Role of AI in Drug Discovery
• Figure 12 : Global Market Shares of AI in Drug Discovery and Development, by Region, 2024
• Figure 13 : Global Market Shares of AI in Pharmaceuticals for Clinical Trial Applications, by Region, 2024
• Figure 14 : Global Market Shares of AI in AI in Pharmaceuticals for Personalized Medicine, by Region, 2024
• Figure 15 : Global Market Shares of Other Applications of AI in Pharmaceuticals, by Region, 2024
• Figure 16 : Global Market Shares of AI in Pharmaceuticals, by Region, 2024
• Figure 17 : North American Market Shares of AI in Pharmaceuticals, by Product Type, 2024
• Figure 18 : North American Market Shares of AI in Pharmaceuticals, by Application, 2024
• Figure 19 : North American Market Shares of AI in Pharmaceuticals, by Country, 2024
• Figure 20 : European Market Shares of AI in Pharmaceuticals, by Product Type, 2024
• Figure 21 : European Market Shares of AI in Pharmaceuticals, by Application, 2024
• Figure 22 : European Market Shares of AI in Pharmaceuticals, by Country, 2024
• Figure 23 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Product Type, 2024
• Figure 24 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Application, 2024
• Figure 25 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Country, 2024
• Figure 26 : RoW Market Shares of AI in Pharmaceuticals, by Product Type, 2024
• Figure 27 : RoW Market Shares of AI in Pharmaceuticals, by Application, 2024
• Figure 28 : RoW Market Shares of AI in Pharmaceuticals, by Sub-Region, 2024
• Figure 29 : Biopharma AI Investment, 2019-2024
• Figure 30 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024
• Figure 31 : Nvidia Corp.: Revenue Share by Country/Region, FY 2024
• Figure 32 : Schrodinger Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 33 : Schrodinger Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 34 : Tempus AI Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 35 : XtalPi Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 36 : XtalPi Inc.: Revenue Share, by Country/Region, FY 2024